Similarly, GAS5 has been shown to be down-regulated in the PBMCs of MG patients, and data have suggested that its overexpression directly up-regulates IL-10 expression to improve the disease, thus suggesting a potential role of GAS5 as a potential therapeutic target or biomarker of treatment outcome in MG [137]. The gene discussed is GAS5; the disease is myasthenia gravis.